Open Access
ARTICLE
LncRNA-ATB Can Be a Biomarker for Diagnosis and Prognosis Evaluation of Non-Small Cell Lung Cancer
Nan Geng1, Wenxia Hu1, Zhikun Liu2, Jingwei Su2, Wenyu Sun3, Shaonan Xie4, Cuimin Ding1,*
1 Department of Respiratory Medicine of the Fourth Hospital of Hebei Medical University, Shijiazhuang, 0540000, China
2 Department of Radiotherapy of the Fourth Hospital of Hebei Medical University, Shijiazhuang, 0540000, China
3 Radiation Biology Laboratory of Case Western Reserve University, Cleveland, 44106, America
4 Department of Thoracic Surgery of the Fourth Hospital of Hebei Medical University, Shijiazhuang, 0540000, China
* Corresponding Author: Cuimin Ding. Email:
Oncologie 2020, 22(4), 245-254. https://doi.org/10.32604/oncologie.2020.014125
Abstract
Objective: This study was set out to inquire into the expression and
clinical significance of lncRNA activated by transforming growth factor β
(LncRNA-ATB) and in cancer tissues of patients with non-small cell lung cancer
(NSCLC). Methods: LncRNA-ATB in cancer tissues and adjacent tissues of 89
NSCLC patients was detected by quantitative real-time polymerase chain reaction
(qRT-PCR), and its clinical diagnostic value in NSCLC was determined by receiver
operating characteristic (ROC) curves. Based on the median expression of LncRNAATB in NSCLC tissues, 89 patients were allocated into high- and low-expression
groups. The 3-year survival rate was calculated using Kaplan-Meier method and logrank test, and compared between lncRNA-ATB high and low expression groups by
Log-rank test. Cox regression quantitatively analyzed the correlation between
lncRNA-ATB and the clinical prognosis of NSCLC patients. Results: LncRNAATB presented notably higher expression in NSCLC tissues as compared to adjacent
tissues (P < 0.05), and was linked to smoking history, TNM stage and greatest tumor
diameter (GTD) (P < 0.05). The cut-off value, sensitivity and specificity, as well as
the area under the curve (AUC) of NSCLC diagnosed by LncRNA-ATB were 2.103,
73.77%, 83.15% and 0.836, respectively. Patients with high lncRNA-ATB
expression (40.00%) showed statistically lower than those with low lncRNA-ATB
expression (63.36%). TNM stage, differentiation degree and lncRNA-ATB
expression were independent variables affecting patient prognosis. Conclusions:
LncRNA-ATB, with increased expression profiles in NSCLC tissues, is involved in
NSCLC progression and associated with unfavourable prognosis of patients, which
can be a plausible tumor marker for NSCLC patients.
Keywords
Cite This Article
Geng, N., Hu, W., Liu, Z., Su, J., Sun, W. et al. (2020). LncRNA-ATB Can Be a Biomarker for Diagnosis and Prognosis Evaluation of Non-Small Cell Lung Cancer.
Oncologie, 22(4), 245–254. https://doi.org/10.32604/oncologie.2020.014125